Adial Pharmaceuticals Osztalék 2024

Mit csinál a(z) Adial Pharmaceuticals?

A(z) Adial Pharmaceuticals Inc was founded in 2010 in Charlottesville, Virginia. The company focuses on the discovery and development of drugs for the treatment of addiction disorders such as alcohol and nicotine dependence. Adial's business model is based on the belief that current therapies for addiction disorders are insufficient and that there is a need for more targeted and effective medications. The company develops drugs that target specific biological processes in the brain associated with addiction disorders. Adial has several divisions, including research and development, manufacturing, and clinical studies. The company has a promising pipeline of candidate molecules in various stages of development. The flagship product of Adial is AD04, which was developed for the treatment of alcohol dependence. AD04 is based on a novel approach called genetic prediction. It targets a specific biological process known as the opioid receptor and blocks it to reduce the craving for alcohol. Adial has recently completed a Phase 3 clinical trial with AD04, which has yielded promising results. The results suggest that AD04 is effective in reducing alcohol consumption in people with the genetic prediction. Adial plans to market AD04 in the USA and Europe. Adial also has a collaboration with the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) in the USA. This collaboration focuses on the development of drugs for the treatment of nicotine dependence. Adial has developed a promising molecule candidate that is currently being tested in Phase 2 clinical trials. Adial also has a division for manufacturing and technology partnerships. The company collaborates with various stakeholders in the pharmaceutical and biotech industry to develop technological solutions that can accelerate the development of new drugs. Overall, Adial Pharmaceuticals has focused on the discovery and development of drugs for the treatment of addiction disorders. The company has a promising pipeline of candidate molecules and has completed clinical trials with its flagship product AD04. Adial is also working in collaboration with renowned institutions such as NIDA of the NIH to expand the scope of its research and development. Adial Pharmaceuticals az egyik legnépszerűbb vállalat az Eulerpool.com-on.